A lot to unpack here, but I wanted to share some research on Professor Bart Meuris who led this study.
Bart Meuris is a cardiac surgeon at the eminent KU Leuven teaching hospital in Belgium. Admedus really couldn't have found a more qualified spokesperson. A look at his publication history tells you that he is an expert in heart valve replacement.
https://www.researchgate.net/scientific-contributions/38704535_Bart_Meuris
Bart's relationship with Admedus dates back to at least 2015;
http://clients2.weblink.com.au/news/pdf_1%5C01664260.pdf
https://admedus.com/uncategorized/05052016/a-day-with-europes-leading-cardiovascular-surgeons/
Bart Meuris has also been heavily involved in studies using the LivaNova 'Perceval' prosthesis. This is an example of one to beat, as it has been implanted in 20,000 patients so far. It was approved in North America in 2015: https://www.businesswire.com/news/home/20150805005634/en/Sorin-Group-Obtains-Health-Canada-Approval-Perceval
Take a look at the vital statistics of the Perceval prosthesis over a 10 year study;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994436/
"Mean effective orifice area (EOA) ranges from 1.4±0.4 to 1.6±0.4 cm2, mean gradients range from 10±5 to 14±6 mmHg and mean peak gradients range from 19±8 to 27±11 mmHg"
Now let's compare to the Admedus offering in today's announcement;
"Effective Orifice Areas (EOA) with a range of 2- 2.5cm2. No regurgitation was observed, and there was a low-pressure gradient across the valves (4-6 mmHg)"
It's only 5 sheep so far, but the increase of Effective Orifice Area (EOA; the size of the 'pipe' for blood to flow through) is outstanding. The upshot of this is that the pressure gradient across the valve is much lower - meaning less leakage and less wear-and-tear.
Admedus has been a royal pain to hold, but this TAVR offering is not to be sneezed at. Coupled with the curved-tissue offerings they are ALREADY bringing to market, revenue is set to increase something substantial.
Best wishes to all
Dr Matt
- Forums
- ASX - By Stock
- AVR
- Ann: Promising Interim Results from TAVR Animal Study
Ann: Promising Interim Results from TAVR Animal Study, page-41
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$11.90 |
Change
1.050(9.68%) |
Mkt cap ! $251.5M |
Open | High | Low | Value | Volume |
$11.00 | $11.90 | $10.85 | $504.4K | 45.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $11.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.90 | 99 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400 | 12.000 |
1 | 335 | 11.900 |
1 | 1000 | 11.750 |
1 | 1000 | 11.500 |
1 | 1000 | 11.300 |
Price($) | Vol. | No. |
---|---|---|
11.980 | 120 | 2 |
12.000 | 2489 | 1 |
12.050 | 9 | 1 |
12.100 | 1220 | 1 |
12.400 | 500 | 1 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |